FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891478207> ?p ?o ?g. }

• W2891478207 abstract "Pancreatic cancer (PC) is the fourth most common cause of cancer death. Combination therapies with classical chemotherapeutic agents improved treatment of advanced PC at the cost of a relevant toxicity, but the 5-year survival rate remains below 5%. Consequently, new therapeutic options for this disease are urgently needed. In this study, we explored the effect of two repurposed drug candidates nelfinavir and nitroxoline, approved for non-anticancer human use, in PC cell lines. Nelfinavir and nitroxoline were tested as single agents, or in combinations with or without erlotinib, a targeted drug approved for PC treatment. The effects of the drugs on the viability of AsPC-1, Capan-2 and BxPC-3 PC cell lines were assessed by MTT. The impact of the treatments on cell cycle distribution and apoptosis was analyzed by flow cytometry. The effects of treatments on proteins relevant in cell cycle regulation and apoptosis were evaluated by western blot. Self-renewal capacity of PC cell lines after drug treatments was assessed using a clonogenic assay. When used as single agents, nelfinavir and nitroxoline decreased viability, affected cell cycle and reduced the expression of relevant cell cycle proteins. The effects on apoptosis were variable among PC cell lines. Moreover, these agents drastically impaired clonogenic activity of the three PC cell lines. Combinations of nelfinavir and nitroxoline, with or without erlotinib, resulted in dose- and cell-dependent synergistic effects on cell viability. These effects were paralleled by cell cycle alterations and more consistent apoptosis induction as compared to single agents. Treatments with drug combinations induced drastic impairment of clonogenic activity in the three cell lines. This study shows that two non-antitumor drugs, nelfinavir and nitroxoline, as single agents or in combination have antitumor effects that appear comparable, or in some case more pronounced than those of erlotinib in three PC cell lines. Our results support repurposing of these approved drugs as single agents or in combination for PC treatment." @default.
• W2891478207 created "2018-09-27" @default.
• W2891478207 creator A5010992446 @default.
• W2891478207 creator A5022113326 @default.
• W2891478207 creator A5027075905 @default.
• W2891478207 creator A5027204492 @default.
• W2891478207 creator A5028617483 @default.
• W2891478207 creator A5029630690 @default.
• W2891478207 creator A5045083114 @default.
• W2891478207 creator A5059444054 @default.
• W2891478207 creator A5060018150 @default.
• W2891478207 creator A5065999376 @default.
• W2891478207 creator A5088919162 @default.
• W2891478207 date "2018-09-21" @default.
• W2891478207 modified "2023-10-12" @default.
• W2891478207 title "Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells" @default.
• W2891478207 cites W1966245361 @default.
• W2891478207 cites W1991028764 @default.
• W2891478207 cites W2002714857 @default.
• W2891478207 cites W2011422070 @default.
• W2891478207 cites W2020621954 @default.
• W2891478207 cites W2064890942 @default.
• W2891478207 cites W2088632292 @default.
• W2891478207 cites W2089329334 @default.
• W2891478207 cites W2092709919 @default.
• W2891478207 cites W2096439168 @default.
• W2891478207 cites W2125175095 @default.
• W2891478207 cites W2135364779 @default.
• W2891478207 cites W2147344769 @default.
• W2891478207 cites W2151092952 @default.
• W2891478207 cites W2167872699 @default.
• W2891478207 cites W2168849655 @default.
• W2891478207 cites W2173889361 @default.
• W2891478207 cites W2174011260 @default.
• W2891478207 cites W2279139042 @default.
• W2891478207 cites W2339415504 @default.
• W2891478207 cites W2517835507 @default.
• W2891478207 cites W2582008652 @default.
• W2891478207 cites W2620141841 @default.
• W2891478207 cites W2622472130 @default.
• W2891478207 cites W2724649723 @default.
• W2891478207 cites W2744108643 @default.
• W2891478207 cites W2755630341 @default.
• W2891478207 doi "https://doi.org/10.1186/s13046-018-0904-2" @default.
• W2891478207 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6151049" @default.
• W2891478207 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30241558" @default.
• W2891478207 hasPublicationYear "2018" @default.
• W2891478207 type Work @default.
• W2891478207 sameAs 2891478207 @default.
• W2891478207 citedByCount "33" @default.
• W2891478207 countsByYear W28914782072019 @default.
• W2891478207 countsByYear W28914782072020 @default.
• W2891478207 countsByYear W28914782072021 @default.
• W2891478207 countsByYear W28914782072022 @default.
• W2891478207 countsByYear W28914782072023 @default.
• W2891478207 crossrefType "journal-article" @default.
• W2891478207 hasAuthorship W2891478207A5010992446 @default.
• W2891478207 hasAuthorship W2891478207A5022113326 @default.
• W2891478207 hasAuthorship W2891478207A5027075905 @default.
• W2891478207 hasAuthorship W2891478207A5027204492 @default.
• W2891478207 hasAuthorship W2891478207A5028617483 @default.
• W2891478207 hasAuthorship W2891478207A5029630690 @default.
• W2891478207 hasAuthorship W2891478207A5045083114 @default.
• W2891478207 hasAuthorship W2891478207A5059444054 @default.
• W2891478207 hasAuthorship W2891478207A5060018150 @default.
• W2891478207 hasAuthorship W2891478207A5065999376 @default.
• W2891478207 hasAuthorship W2891478207A5088919162 @default.
• W2891478207 hasBestOaLocation W28914782071 @default.
• W2891478207 hasConcept C117262875 @default.
• W2891478207 hasConcept C121608353 @default.
• W2891478207 hasConcept C126322002 @default.
• W2891478207 hasConcept C142462285 @default.
• W2891478207 hasConcept C185592680 @default.
• W2891478207 hasConcept C190283241 @default.
• W2891478207 hasConcept C203014093 @default.
• W2891478207 hasConcept C2778087573 @default.
• W2891478207 hasConcept C2779438470 @default.
• W2891478207 hasConcept C2780210213 @default.
• W2891478207 hasConcept C2780783641 @default.
• W2891478207 hasConcept C2781160516 @default.
• W2891478207 hasConcept C2909325608 @default.
• W2891478207 hasConcept C29537977 @default.
• W2891478207 hasConcept C2993143319 @default.
• W2891478207 hasConcept C3013748606 @default.
• W2891478207 hasConcept C502942594 @default.
• W2891478207 hasConcept C53227056 @default.
• W2891478207 hasConcept C55493867 @default.
• W2891478207 hasConcept C62112901 @default.
• W2891478207 hasConcept C71924100 @default.
• W2891478207 hasConcept C98274493 @default.
• W2891478207 hasConceptScore W2891478207C117262875 @default.
• W2891478207 hasConceptScore W2891478207C121608353 @default.
• W2891478207 hasConceptScore W2891478207C126322002 @default.
• W2891478207 hasConceptScore W2891478207C142462285 @default.
• W2891478207 hasConceptScore W2891478207C185592680 @default.
• W2891478207 hasConceptScore W2891478207C190283241 @default.
• W2891478207 hasConceptScore W2891478207C203014093 @default.
• W2891478207 hasConceptScore W2891478207C2778087573 @default.
• W2891478207 hasConceptScore W2891478207C2779438470 @default.
• W2891478207 hasConceptScore W2891478207C2780210213 @default.

• next